Scarica l'app Stockscreener
0.161
2.55%
0.004
Dopo l'orario di chiusura:
.16
-0.001
-0.62%
Medicus Pharma Ltd Borsa (MDCX) Ultime notizie
Medicus Pharma Ltd. (MDCX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Medicus Pharma Ltd. Submits Optimized Seamless Phase 2B/3 Registration-Intent Protocol to FDA for Teverelix in Advanced Prostate Cancer - marketscreener.com
Small cap wrap: Medicus Pharma, BioHarvest, Ondine... - Proactive financial news
Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA - Yahoo Finance
Medicus Pharma submits seamless Phase 2b/3 protocol for Teverelix - Investing.com
A prostate cancer plan could reduce enrollment from about 1,500 to about 600 patients if FDA agrees. - Stock Titan
Price to book forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Medicus's Pfizer Deal Was Not a Fire Sale: A Strategic Bet on De-Risked ADC Drug - Streetwise Reports
Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients - Yahoo Finance
Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus - AOL.ca
Medicus Pharma to focus SkinJect development on Gorlin syndrome By Investing.com - Investing.com Australia
Medicus Pharma to focus SkinJect development on Gorlin syndrome - Investing.com
Medicus Pharma Shifts SkinJect Focus to Gorlin Syndrome | MDCX Stock News - Stock Titan
Top Medicus Pharma (MDCX) Competitors 2026 - MarketBeat
Press Release: Medicus Pharma Announces $22 Million Non-Dilutive Financing - Moomoo
Dr. Raza Bokhari Discloses Investment at Medicus Pharma Ltd. with 5.3% Stake - TradingView
Form 8K Medicus Pharma Ltd For: 14 September By Investing.com - Investing.com Australia
Medicus Pharma ends standby equity purchase agreement with Yorkville By Investing.com - Investing.com India
How big is Medicus Pharma (MDCX) CEO Raza Bokhari's stake? - Stock Titan
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI - Yahoo Finance
FDA Clears Medicus SkinJect Study for Gorlin Syndrome - MyChesCo
Inside the deal: How a Montco biotech secured a Pfizer drug candidate - The Business Journals
Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com Nigeria
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com Nigeria
Medicus Pharma posts phase 2 study results for skin cancer drug By Investing.com - Investing.com Australia
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Nigeria
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Proactive financial news
Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study - Yahoo Finance
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment - Proactive financial news
Conshohocken's Medicus Pharma Picks Up a Discarded Pfizer Cancer Drug in a Deal Worth More Than $1 Billion - BioBuzz
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - BioBuzz
Medicus Pharma Ltd. Posts Abridged Phase 2 Clinical Study Report for SkinJect® SKNJCT-003, Advances Gorlin Syndrome Development Plan | MDCX Stock News - Quiver Quantitative
FDA authorizes the next study of a skin cancer patch - Stock Titan
MDCX Stock Price, Quote & Chart - ChartMill
Medicus Pharma (MDCX) grants COO 735K shares and options - Stock Titan
Medicus Pharma (NASDAQ: MDCX) awards stock and options to its chief medical officer - Stock Titan
Medicus Pharma (MDCX) hands CSO 588K shares and 100K options - Stock Titan
Medicus Pharma (MDCX) CEO adds millions of shares and options in 2026 grant - Stock Titan
CFO adds Medicus Pharma (MDCX) stock and options - Stock Titan
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs - Proactive financial news
Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy - Yahoo Finance
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com Nigeria
Medicus Pharma shifts focus to precision oncology with CD228V - Investing.com
Medicus Pharma Ltd. Repositions as Precision Oncology-Led Biotech, Prioritizes CD228V, SkinJect and Teverelix Programs - Quiver Quantitative
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - ACCESS Newswire
Price to sales forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
MDCX Should I Buy - Intellectia AI
Medicus Pharma Ltd. Common Stock (NASDAQ: MDCX) Stock Price, News & Analysis - Kalkine
Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal - AllSci
Pfizer Licenses Discontinued Cancer Drug to Medicus Pharma in Deal Valued Over $1 Billion - finance.biggo.com
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion - Benzinga
Medicus Pharma Secures Global Rights to Pfizer’s CD228V with $12M Initial Payment and $15M Commitment - kalkinemedia.com
$Medicus Pharma (MDCX.US)$ - Moomoo
1.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):